Markets
MA Stock Indexes
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Local Stocks
Emergent Biosolutions (NY: EBS)
14.56 USD  UNCHANGED
Official Closing Price  /  Updated: 6:40 PM EDT, May 17, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Emergent Biosolutions
 
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Sixth Annual SOUTHWESTERN SHOWCASE Investor Conference To Take Place on November 19-20, 2008 in Dallas
October 20, 2008
Venue Brings Together Quality Companies with Professional Investors Read More
from Business Wire News Releases
Emergent BioSolutions to Release Third Quarter 2008 Financial Results and Conduct a Conference Call on November 6, 2008
October 16, 2008
from Business Wire News Releases
U.S. Government Issues Declaration Covering Emergent BioSolutions' BioThrax(R) and Anthrax Immune Globulin under Prep Act
October 09, 2008
HHS Secretary Determines That Potential Threat of Exposure to Anthrax Constitutes a Public Health Emergency Read More
from Business Wire News Releases
U.S. Government to Purchase Additional 14.5 Million Doses of BioThrax under New Contract Valued at up to $404 Million
October 01, 2008
New Contract Extends USG's Commitment to Purchase BioThrax Through 3Q 2011 and is a Follow-on to the Existing 2007, $448 Million Contract Read More
from Business Wire News Releases
Emergent BioSolutions Signs Contract with BARDA/NIAID, Valued at Up to $29.7 Million, to Fund Development of AV7909 - A Next Generation Anthrax Vaccine
September 26, 2008
--AV7909 Contract is in Addition to Recently Announced $24 Million Development Contract for Anthrax Monoclonal and Pending Proposal to Supply HHS with Up to 25 Million Doses of a Recombinant Anthrax... Read More
from Business Wire News Releases
Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
September 12, 2008
from PR Newswire
Emergent BioSolutions Notified by HHS That Its Proposal to Provide 25 Million Doses of Its Recombinant Anthrax Vaccine Is Technically Acceptable and Within the Competitive Range
September 12, 2008
from Business Wire News Releases
Emergent BioSolutions Receives $24 Million Development Contract from the Department of Health and Human Services to Fund Continued Development of Anthrax Monoclonal Antibody
September 03, 2008
from Business Wire News Releases
Emergent BioSolutions Reports Financial Results for Second Quarter 2008
August 07, 2008
-- Continued delivery of BioThrax(R) doses under current HHS contract drives 88 percent increase in Q2 2008 revenue over Q2 2007 -- Recent acquisitions expand anthrax franchise -- Financial outlook for... Read More
from Business Wire News Releases
Emergent BioSolutions to Present at the BMO Capital Markets Focus on Healthcare Conference on August 6, 2008
August 05, 2008
from Business Wire News Releases
Emergent BioSolutions Submits Proposal in Response to HHS RFP for Development and Procurement of a Recombinant Protective Antigen Anthrax Vaccine
July 31, 2008
The company's submission provides the U.S. Government with the critical option to select a domestic source to meet planned procurement of 25 million doses of rPA vaccine Read More
from Business Wire News Releases
Statement by Emergent BioSolutions in Response to Attempt by Protein Sciences Corporation to Terminate Asset Purchase Transaction
July 29, 2008
from Business Wire News Releases
Protein Sciences Announces Termination of Deal to Sell to Emergent BioSolutions
July 29, 2008
from PR Newswire
Emergent BioSolutions to Release Second Quarter 2008 Financial Results and Conduct a Conference Call on August 7, 2008
July 25, 2008
from Business Wire News Releases
Emergent BioSolutions Awarded Two Grants from NIAID to Support Development of the Company's Recombinant Botulinum Vaccine (rBOT) and Next Generation Anthrax Vaccine (NGAV) Candidates
July 24, 2008
The rBOT Grant is the First Government Award in Support of the Company's Botulinum Vaccine Program Read More
from Business Wire News Releases
Emergent BioSolutions and the University of Oxford Form Joint Venture to Develop an Advanced Tuberculosis Vaccine with Funding from Wellcome Trust and Aeras Global TB Vaccine Foundation
July 23, 2008
-- Wellcome Trust and Aeras Global TB Vaccine Foundation have agreed to provide GBP 8 million in funding for Phase IIb clinical trial that is expected to commence in 2009 -- The vaccine candidate,... Read More
from Business Wire News Releases
Protein Sciences Responds to Emergent BioSolutions Lawsuit
July 10, 2008
from PR Newswire
Emergent BioSolutions Initiates Lawsuit Against Protein Sciences and Its Senior Management Regarding Delayed Asset Acquisition
July 09, 2008
-- Suit alleges fraud by PSC management and contract breaches by PSC -- Emergent seeks immediate repayment of $10 million bridge loan secured by all of PSC's assets plus other relief Read More
from Business Wire News Releases
Emergent BioSolutions and the European Corporate Security Association (ECSA) Sponsor a Conference on Bioterrorism
June 05, 2008
Attendees Include Key Officials from the European Union, International and Diplomatic Institutions Read More
from Business Wire News Releases
Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate
June 05, 2008
-- Study designed to confirm safety and immunogenicity of vaccine manufactured at the large-scale commercial facility planned for launch -- Phase III trials are expected to begin next year Read More
from Business Wire News Releases
Emergent BioSolutions to Webcast Presentation at the Jefferies and Company 2nd Annual Healthcare Conference on June 25, 2008
June 04, 2008
from Business Wire News Releases
Emergent BioSolutions to Acquire Protein Sciences' Phase III Recombinant Flu Vaccine Candidate, FluBlok(R), and Related Novel Platform Technology
May 27, 2008
-- FluBlok BLA granted fast track status and priority review by FDA; would be the first licensed recombinant hemagglutinin cell culture influenza vaccine -- Emergent plans to continue Protein Sciences'... Read More
from Business Wire News Releases
Emergent BioSolutions Reports Financial Results for First Quarter 2008
May 07, 2008
-- Continued delivery of BioThrax(R) doses under current HHS contract drives 62 percent increase in first quarter revenue -- Continued investment in pipeline through internally generated cash flows --... Read More
from Business Wire News Releases
Emergent BioSolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate and Technology
May 05, 2008
Acquisition positions Emergent to offer the U.S. Government a domestic source for an advanced anthrax vaccine candidate to meet planned procurement of 25 million doses of rPA vaccine Read More
from Business Wire News Releases
Baker Hughes Declares Regular Quarterly Dividend
April 24, 2008
from PR Newswire
Baker Hughes Announces First Quarter Results
April 22, 2008
from PR Newswire
BHI Acquires Reservoir Consulting Firms
April 16, 2008
Dr. D. Nathan Meehan Named VP Reservoir Technology and Consulting Read More
from PR Newswire
Emergent BioSolutions to Release First Quarter 2008 Financial Results and Conduct a Conference Call On May 7, 2008
April 10, 2008
from Business Wire News Releases
Emergent BioSolutions to Hold Annual Meeting of Stockholders Wednesday, May 21, 2008 at 10:00 am Eastern
April 08, 2008
from Business Wire News Releases
Baker Hughes Announces March 2008 Rig Counts
April 07, 2008
from PR Newswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here